Contribution of myeloperoxidase to smoking-dependent vascular inflammation

Proceedings of the American Thoracic Society

Volumn 5, Issue 8, 2008, Pages 820-823

  Rudolph, Tanja K ^a   Rudolph, Volker ^a   Baldus, Stephan ^a  

^a UNIVERSITY HEART CENTER HAMBURG   (Germany)

Author keywords

Leukocytes; Myeloperoxidase; Smoking

Indexed keywords

CIGARETTE SMOKE CONDENSATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYELOPEROXIDASE; NICOTINE; REACTIVE OXYGEN METABOLITE;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CAROTID ARTERY OBSTRUCTION; CONFERENCE PAPER; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HEART FAILURE; HEART INFARCTION; HUMAN; MACROPHAGE; NEUTROPHIL; OXIDATIVE STRESS; PERIPHERAL VASCULAR DISEASE; PROGNOSIS; SMOKING; VASCULITIS;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; HUMANS; INFLAMMATION; NEUTROPHILS; PEROXIDASE; SMOKING;

EID: 57349100831     PISSN: 15463222     EISSN: None     Source Type: Journal    
DOI: 10.1513/pats.200807-063TH     Document Type: Conference Paper

References (56)

1. Tachmes L, Fernandez RJ, Sackner MA. Hemodynamic effects of smoking cigarettes of high and low nicotine content. Chest 1978;74:243-246.
2. Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. BMJ 1989;298:784-788.
3. Scheffler E, Wiest E, Woehrle J, Otto I, Schulz I, Huber L, Ziegler R, Dresel HA. Smoking influences the atherogenic potential of low-density lipoprotein. Clin Investig 1992;70:263-268.
4. Harats D, Ben-Naim M, Dabach Y, Hollander G, Stein O, Stein Y. Cigarette smoking renders LDL susceptible to peroxidative modification and enhanced metabolism by macrophages. Atherosclerosis 1989;79:245-252.
5. Marasini B, Biondi ML, Barbesti S, Zatta G, Agostoni A. Cigarette smoking and platelet function. Thromb Res 1986;44:85-94.
6. Foo LC, Roshidah I, Aimy MB. Platelets of habitual smokers have reduced susceptibility to aggregating agent. Thromb Haemost 1991;65:317-319.
7. Shen Y, Rattan V, Sultana C, Kalra VK. Cigarette smoke condensate-induced adhesion molecule expression and transendothelial migration of monocytes. Am J Physiol 1996;270:H1624-H1633.
8. Kalra VK, Ying Y, Deemer K, Natarajan R, Nadler JL, Coates TD. Mechanism of cigarette smoke condensate induced adhesion of human monocytes to cultured endothelial cells. J Cell Physiol 1994;160:154-162.
9. Blann AD, Steele C, McCollum CN. The influence of smoking on soluble adhesion molecules and endothelial cell markers. Thromb Res 1997;85:433-438.
10. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000;87:840-844.
11. Heitzer T, Just H, Munzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation 1996;94:6-9.
12. Zeiher AM, Schachinger V, Minners J. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function. Circulation 1995;92:1094-1100.
13. Lavi S, Prasad A, Yang EH, Mathew V, Simari RD, Rihal CS, Lerman LO, Lerman A. Smoking is associated with epicardial coronary endothelial dysfunction and elevated white blood cell count in patients with chest pain and early coronary artery disease. Circulation 2007;115:2621-2627.
14. Neunteufl T, Heher S, Kostner K, Mitulovic G, Lehr S, Khoschsorur G, Schmid RW, Maurer G, Stefenelli T. Contribution of nicotine to acute endothelial dysfunction in long-term smokers. J Am Coll Cardiol 2002;39:251-256.
15. Heitzer T, Baldus S, von Kodolitsch Y, Rudolph V, and Meinertz T. Systemic endothelial dysfunction as an early predictor of adverse outcome in heart failure. Arterioscler Thromb Vasc Biol 2005;25:1174-1179.
16. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-1906.
17. Parry H, Cohen S, Schlarb JE, Tyrrell DA, Fisher A, Russell MA, Jarvis MJ. Smoking, alcohol consumption, and leukocyte counts. Am J Clin Pathol 1997;107:64-67.
18. Terashima T, Wiggs B, English D, Hogg JC, van Eeden SF. The effect of cigarette smoking on the bone marrow. Am J Respir Crit Care Med 1997;155:1021-1026.
19. Freedman DS, Flanders WD, Barboriak JJ, Malarcher AM, Gates L. Cigarette smoking and leukocyte subpopulations in men. Ann Epidemiol 1996;6:299-306.
20. Madjid M, Awan I, Willerson JT, Casscells SW. Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol 2004;44:1945-1956.
21. Brown DW, Giles WH, Croft JB. White blood cell count: an independent predictor of coronary heart disease mortality among a national cohort. J Clin Epidemiol 2001;54:316-322.
22. Iho S, Tanaka Y, Takauji R, Kobayashi C, Muramatsu I, Iwasaki H, Nakamura K, Sasaki Y, Nakao K, Takahashi T. Nicotine induces human neutrophils to produce IL-8 through the generation of peroxynitrite and subsequent activation of NF-kappaB. J Leukoc Biol 2003;74:942-951.
23. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994;94:437-444.
24. Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol 2005;77:598-625.
25. Brown KE, Brunt EM, Heinecke JW. Immunohistochemical detection of myeloperoxidase and its oxidation products in Kupffer cells of human liver. Am J Pathol 2001;159:2081-2088.
26. Green PS, Mendez AJ, Jacob JS, Crowley JR, Growdon W, Hyman BT, Heinecke JW. Neuronal expression of myeloperoxidase is increased in Alzheimer's disease. J Neurochem 2004;90:724-733.
27. Eiserich JP, Hristova M, Cross CE, Jones AD, Freeman BA, Halliwell B., van der Vliet A. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 1998;391:393-397.
28. van Dalen CJ, Whitehouse MW, Winterbourn CC, Kettle AJ. Thiocyanate and chloride as competing substrates for myeloperoxidase. Biochem J 1997;327:487-492.
29. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, Topol EJ, Sprecher DL, Hazen SL. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001;286:2136-2142.
30. Meuwese MC, Stroes ES, Hazen SL, van Miert JN, Kuivenhoven JA, Schaub RG, Wareham NJ, Luben R, Kastelein JJ, Khaw KT, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007;50:159-165.
31. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, Simoons ML, Hamm CW. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003;108:1440-1445.
32. Abu-Soud HM, Hazen SL. Nitric oxide is a physiological substrate for mammalian peroxidases. J Biol Chem 2000;275:37524-37532.
33. Eiserich JP, Baldus S, Brennan ML, Ma W, Zhang C, Tousson A, Castro L, Lusis AJ, Nauseef WM, White CR, et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 2002;296:2391-2394.
34. Daphna EM, Michaela S, Eynat P, Irit A, Rimon S. Association of myeloperoxidase with heparin: oxidative inactivation of proteins on the surface of endothelial cells by the bound enzyme. Mol Cell Biochem 1998;183:55-61.
35. Baldus S, Eiserich JP, Mani A, Castro L, Figueroa M, Chumley P, Ma W, Tousson A, White CR, Bullard DC, et al. Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. J Clin Invest 2001;108:1759-1770.
36. Ischiropoulos H. Biological tyrosine nitration: a pathophysiological function of nitric oxide and reactive oxygen species. Arch Biochem Biophys 1998;356:1-11.
37. Magnusson MK, Mosher DF. Fibronectin: structure, assembly, and cardiovascular implications. Arterioscler Thromb Vasc Biol 1998;18:1363-1370.
38. Hazen SL, Zhang R, Shen Z, Wu W, Podrez EA, MacPherson JC, Schmitt D, Mitra SN, Mukhopadhyay C, Chen Y, et al. Formation of nitric oxide-derived oxidants by myeloperoxidase in monocytes: pathways for monocyte-mediated protein nitration and lipid peroxidation in vivo. Circ Res 1999;85:950-958.
39. Exner M, Hermann M, Hofbauer R, Hartmann B, Kapiotis S, Gmeiner B. Thiocyanate catalyzes myeloperoxidase-initiated lipid oxidation in LDL. Free Radic Biol Med 2004;37:146-155.
40. Schmitt D, Shen Z, Zhang R, Colles SM, Wu W, Salomon RG, Chen Y, Chisolm GM, Hazen SL. Leukocytes utilize myeloperoxidase-generated nitrating intermediates as physiological catalysts for the generation of biologically active oxidized lipids and sterols in serum. Biochemistry 1999;38:16904-16915.
41. Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Horkko S, Barnard J, Reynolds WF, Topol EJ, DiDonato JA, Hazen SL. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007;13:1176-1184.
42. George SJ. Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis. Expert Opin Investig Drugs 2000;9:993-1007.
43. Fu X, Kassim SY, Parks WC, Heinecke JW. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 2001;276:41279-41287.
44. Askari AT, Brennan ML, Zhou X, Drinko J, Morehead A, Thomas JD, Topol EJ, Hazen SL, Penn MS. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med 2003;197:615-624.
45. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003;349:1595-1604.
46. Brevetti G, Schiano V, Laurenzano E, Giugliano G, Petretta M, Scopacasa F, Chiariello M. Myeloperoxidase, but not C-reactive protein, predicts cardiovascular risk in peripheral arterial disease. Eur Heart J 2008;29:224-230.
47. Exner M, Minar E, Mlekusch W, Sabeti S, Amighi J, Lalouschek W, Maurer G, Bieglmayer C, Kieweg H, Wagner O, et al. Myeloperoxidase predicts progression of carotid stenosis in states of low high-density lipoprotein cholesterol. J Am Coll Cardiol 2006;47:2212-2218.
48. Khan SQ, Kelly D, Quinn P, Davies JE, Ng LL. Myeloperoxidase aids prognostication together with N-terminal pro-B-type natriuretic peptide in high-risk patients with acute ST elevation myocardial infarction. Heart 2007;93:826-831.
49. Loria V, Dato I, Graziani F, Biasucci LM. Myeloperoxidase: a new biomarker of inflammation in ischemic heart disease and acute coronary syndromes. Mediators Inflamm [serial on the Internet] 2008 [accessed June 2, 2008];2008. Article 135625. Available from: http://www.hindawi.com/ GetArticle.aspx?doi=10.1155/2008/135625
50. Mocatta TJ, Pilbrow AP, Cameron VA, Senthilmohan R, Frampton CM, Richards AM, Winterbourn CC. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol 2007;49:1993-2000.
51. Nambi V. The use of myeloperoxidase as a risk marker for atherosclerosis. Curr Atheroscler Rep 2005;7:127-131.
52. Rudolph V, Rudolph TK, Hennings JC, Blankenberg S, Schnabel R, Steven D, Haddad M, Knittel K, Wende S, Wenzel J, et al. Activation of polymorphonuclear neutrophils in patients with impaired left ventricular function. Free Radic Biol Med 2007;43:1189-1196.
53. Tang WH, Tong W, Troughton RW, Martin MG, Shrestha K, Borowski A, Jasper S, Hazen SL, Klein AL. Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J Am Coll Cardiol 2007;49:2364-2370.
54. Stefanescu A, Braun S, Ndrepepa G, Koppara T, Pavaci H, Mehilli J, Schomig A, Kastrati A. Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease. Am Heart J 2008;155:356-360.
55. Cavusoglu E, Ruwende C, Eng C, Chopra V, Yanamadala S, Clark LT, Pinsky DJ, Marmur JD. Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. Am J Cardiol 2007;99:1364-1368.
56. Morrow DA, Sabatine MS, Brennan ML, de Lemos JA, Murphy SA, Ruff CT, Rifai N, Cannon CP, Hazen SL. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J 2008;29:1096-1102.